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Primary malignant pericardial mesothelioma is an extremely rare tumour. One of the largest 
autopsy series including about 500,000 cases gave an incidence of primary pericardial 
tumours of <0.0022% (Gossinger et al., 1998). However, it accounts for approximately 2-3% 
of all cardiac and pericardial primary tumours being the third tumour after angiosarcoma 
and rhabdomiosarcoma (Karadzic et al., 2005; Papi et al., 2005).  
Mesothelioma arises from the serous epithelial cell of the mesothelium. The most common 
sites for this malignancy include the pleura (60-70%) and the peritoneum (30-35%). Primary 
pericardial mesothelioma accounts for only about 1% of all mesotheliomas (Karadzic et al., 
2005; Papi et al., 2005). 
Approximately 200 cases have been described in literature, of which most have been 
reported as case studies. The majority of diagnoses occur in the fourth to seventh decades of 
life with a median age of 46 years (Nilsson & Rasmuson, 2009) and on average, tends to 
develop in fairly young people compared to pleural or peritoneal mesothelioma. The male-
to-female ratio is nearly 2:1, lower than the ratio of approximately 3.5:1 for mesotheliomas of 
the pleura.  
The higher proportion of women suggests that the link with asbestos exposure is weaker for 
pericardial than for pleural mesothelioma, or that some pericardial mesotheliomas are 
pathogenetically distinct from their pleural counterparts (Burke et al., 1995). The etiology of 
malignant pericardial mesothelioma is not completely known. No obvious relationship 
between asbestos exposure and the development of pericardial mesothelioma has been 
established due, in part, to the very small number of cases reported (Kaul et al., 1994). An 
example of this is a recent article published by Nilsson et al., 2009, where they presented a case 
report and review of 29 primary pericardial mesotheliomas in English literature from 1993 
through to 2008. They found that most of the reviewed articles contained no information about 
asbestos exposure and that only three cases were reported with known exposure to asbestos 
and 11 were reported with no known exposure (Nilsson et al., 2009), Table 1. 
Furthermore, pericardial malignant mesothelioma has been described in patients with a 
prior history of irradiation showing pericardial effusion (Bendek et al., 2010; Yildirim et al., 
2010). A rare association with pericardial mesothelioma and tuberculosis has also been 
reported (Narayanan et al., 1972). 
www.intechopen.com
Mesotheliomas – Synonyms and Definition, Epidemiology, Etiology,  
Pathogenesis, Cyto-Histopathological Features, Clinic, Diagnosis, Treatment, Prognosis 
 
40
Exposure to asbestos n   %
Exposure 3/14 21 
No known exposure 11/14 79 
Not mentioned 16/30 53 
Table 1. Asbestos exposure and primary pericardial mesothelioma 
2. Clinical presentation 
Symptoms arising from primary pericardial mesothelioma usually result from constriction 
of the heart or compression of surrounding structures, ranging from dyspnoea, cough, 
dysphagia, orthopnoea and chest pain (Aggarwal et al.,1991). The onset of symptoms is 
usually insidious. Common clinical manifestations of pericardial mesothelioma are 
constrictive pericarditis, pericardial effusion, cardiac tamponade and heart failure caused by 
myocardial infiltration (Suman et al., 2004). Compression of coronary arteries and local 
spread of the disease to surrounding large vessels can result in additional symptoms.  
As with symptoms, the majority of physical findings are nonspecific. Tachycardia (a heart 
rate of more than 90 beats per minute) is usually present. Heart sounds may be attenuated if 
pericardial fluid is present. Clinically significant tamponade produces jugular venous 
distension, hypotension or even shock. A key diagnostic finding for tamponade is pulsus 
paradoxus, defined as an exaggeration (more than 10 mmHg) of the normal variation during 
the inspiratory phase of respiration, in which the blood pressure declines as one inhales and 
increases as one exhales, and is often palpable in muscular arteries. Sometimes, pulsus 
paradoxus can be caused by other pathologies, such as asthma, COPD, superior vena cava 
obstruction, pulmonary embolism or anaphylactic shock.  
Additionally, distant metastasis, conduction blockade due to myocardial infiltration and 
tumour embolism causing neurological deficits have also been reported (Szczechowski et al., 
1992). Metastases are present in about 25-45% of the patients and involve regional lymph 
nodes, lung and kidney (Karadzic et al., 2005; Lagrotteria et al., 2005). 
3. Diagnosis 
Diagnosis of the disease can be challenging because of nonspecific symptoms and therefore 
usually only detected at an advanced stage. Usually, tumour presentation consists of 
coalescent irregular lobular masses that obliterate the pericardial space and tend to constrict 
the heart. Although a mild infiltration into the subepicardial muscle may occur, the 
underlying myocardium is frequently not affected. The malignant involvement of 
pericardium may lead to the development of pericardial effusion, which results from 
blockage of venous and lymphatic circulation of pericardial fluid.  
Often, a multimodal imaging approach, including echocardiography, computed 
tomography (CT), magnetic resonance imaging (MRI) and FDG-PET scans, is required. 
Chest radiography of patients reveals cardiomegaly, an irregular cardiac silhouette or 
diffuse mediastinal enlargement. Transthoracic echocardiography is the mainstay imaging 
technique for cardiac tumour detection. Although generally robust, it carries several well-
described limitations, including operator dependence, restricted field of view and occasional 
limited imaging of the right heart chambers. Transesophageal echocardiography improves 
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image quality considerably, but is more invasive and carries a restricted field of view. CT 
scan can demonstrate the extent of the cardiac tumour, the extent of pericardial thickening, 
the mediastinal lymph node and the extracardiac lesions, Figure 1. These can be useful in 
distinguishing primary pericardial tumours from other causes of constrictive pericarditis. 
Cardiovascular magnetic resonance imaging is the reference non-invasive imaging 
technique for assessment and characterization of a suspected cardiac mass. It allows 
accurate confirmation of the presence of a space occupying lesion, localization and 
assessment of the extent of involvement, evaluation of the functional impact of the lesions, 
as well as tissue characterization, Figure 2. Such information is important not only for 
diagnosis, but also determination of prognosis and in planning of therapy (Randhawa et al., 
2011). Integrated positron-emission tomography (PET)/Computed tomography (CT) 
imaging has not established itself in routine evaluation, probably due to their low 
frequency. However, in a recent report, PET-CT was useful in the staging and preoperative 
evaluation of pleural or pericardial mesothelioma, detection of unsuspected nodal and 
occult distant metastases (Ost et al., 2008).  
 
Fig. 1. Axial contrast-enhanced chest CT scan (mediastinal window) shows a soft-tissue 
mass with homogenous enhancement that encases the ascending aorta and right pulmonary 
artery. The mass is compressing the right atrium (arrows). 
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Fig. 2. Contrast-enhanced short-axis steady-state free precession MR image, demonstrates 
extensive pericardial involvement of the tumour that encases the ventricles and also 
compresses the right ventricle. It is possible to differentiate the myocardium (arrowheads) 
from the mass (asterisks). In this sequence, liquids show high attenuation and only minimal 
pericardial fluid is seen (arrow). RV: right ventricle; LV: left ventricle. 
The diagnosis of the disease is made as a result of the pathologic assessment of pericardial 
fluid or tissue generally obtained with the guidance of echocardiogram, ultrasonography or 
CT scans. Moreover, cytological examination, immunohistochemistry and the high 
pericardial hialuronic acid content of the pericardial aspirate can be diagnostic. As with any 
tumour, reliable diagnosis of mesothelioma depends on obtaining adequate and 
representative tissue samples. Antemortem diagnosis is notoriously difficult because the 
clinical presentation is nonspecific, the radiological findings are sometimes non-contributory 
and the cytological analysis of pericardial fluid is often inconclusive. In only 10-20% of cases 
can the diagnosis be made before the death of the patient (Papi et al., 2005). It is important to 
differentiate between malignancy and mesothelial reactive hyperplasia associated with 
inflammatory disease. In biopsy specimens, features that indicate the presence of a 
malignancy are infiltration of deep tissues, atypical cells, necrosis and confluent forms. In 
these cases it is useful to obtain additional anamnesis, clinical and radiological information. 
Immunohistochemistry has a limited role and the more useful antibodies have diagnostic 
sensitivity and specificity < 90% (table 2). 
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Antibody Sensitivity (%) Specificity (%) 
Epithelial membrane antigen 74 89
p53 58 91
Desmin 83 83
Table 2. Antibodies distinguishing between malignant mesothelioma and reactive 
mesothelial hyperplasia (Addis B & Roche H, 2009).  
On microscopy, malignant mesotheliomas of the pericardium resemble pleural 
mesotheliomas. Mesotheliomas are divided into epithelial, mixed (biphasic) and sarcomatous 
types on the basis of histologic growth patterns, Figure 3,4. The less common mixed and 
sarcomatous variants show poorer survival. Immunohistochemically, almost 100% of pleural 
mesotheliomas express cytokeratin in epitheloid areas. Sarcomatoid cells express cytokeratin 
in about 75% of cases, vimentin is preferentially expressed in the spindle cell areas and 
epithelioid membrane antigen (EMA) is frequently present in the epitheloid areas. With 
pericardial mesotheliomas, EMA and vimentin are present in fewer than 50% of pericardial 
cases. As with pleural mesothelioma, a panel of antibodies should be used for differential 
diagnosis with metastatic pericardial tumours, so much frequent than mesothelioma. For 
adenocarcinoma, the most common metastatic pericardial tumour, a panel of positive (CK5/6, 
calretinina) and negative (CEA, ber-EP4 y CD15) antibodies allow the diagnosis of 
mesothelioma in the context of the morphologic findings. In this case, antibodies usually 
positive in epithelial mesothelioma are presented in Table 3 (Addis & Roche, 2009).  
 
Antibody Sensitivity (%) Specificity (%)
CK5/6 83 85
Calretinin 82 85
HBME 1 85 43
Thrombomodulin 61 80
N-cadherin 78 84
Wilms tumour product-1 77 96
Table 3. Antibodies usually positive in epithelial mesothelioma. 
 
Fig. 3. Positivity for calretinin in neoplastic cells of epithelial mesothelioma.  
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Fig. 4. Epithelial mesothelioma in invasive pattern. Hematoxylin-eosin x 200. 
4. Treatment and prognosis 
Pericardial mesothelioma is a highly aggressive tumour with global survival of less than 6-
12 months, depending on histological type, tumour stage, performance status and treatment, 
and other factors, such as gender and age (Papi et al., 2005; Suman et al., 2004). Its molecular 
profile indicates that most of the known genes for radio- and chemoresistance are 
overexpressed (Roe et al., 2009). Treatment tends to be mainly palliative rather than radical 
and based on surgery, chemotherapy and radiotherapy. However, despite best efforts, no 
significant difference has been achieved in regards to prognosis.  
Surgery plays a limited role as the disease is often locally advanced when diagnosis is 
reached. Its main role is therefore to control symptoms, as in the case of partial 
pericardiectomy in cardiac tamponade (Vigneswaran et al., 2000).  
Treatment options for the control of malignant pericardial effusions or tamponade should 
be individualized to maximize symptom relief and minimal impact in quality of life. 
Several techniques have been used, percutaneous pericardiocentesis, pericardial sclerosis, 
subxiphoid pericardial window, pericardiectomy or pericardiectomy by thoracotomy or 
video-assisted thoracoscopy. However, a retrospective comparison of cases published in 
1998 by Girardi, showed that periocardiocentesis with intrapericardial sclerotherapy was 
as effective as open surgical drainage for the management of malignant pericardial 
effusions and also showed similar rates of complications (Girardi et al., 1997). Surgical 
drainage is desirable in patients with intrapericardial bleeding and in those with clotted 
hemopericardium or thoracic conditions that make needle drainage difficult or ineffective. 
If treatment is indicated for management of tamponade, percutaneous subxiphoid 
pericardiocentesis is the treatment of choice in the acute setting, guided by 
echocardiography. Recurrent pericardial effusion occurs in approximately 21-50% of cases 
(Anderson et al., 2001; Tsang et al., 2000). Limited cases suggest rates of pericardial fluid 
reaccumulation at 30 days ranging 5-33% after periocardiocentesis and intrapericardial 
treatment with sclerosing drugs versus more than 50% in cases treated with pericardial 
drainage alone (Anderson et al., 2001). Several sclerosing agents have been used, 
tetracycline, bleomycin, thiotepa, mitoxantrone, docetaxel, among others. Some cases may 
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required three or more treatments to achieve adequate sclerosis. A prospective 
comparison study of doxycicline versus bleomycin showed a similar rate of success, but 
less morbidity in cases treated with bleomycin, especially in severe retroesternal chest 
pain, 70% of patients treated with tetracyclines versus 0% with bleomycin (Liu et al., 
1996).  
 
Fig. 5. Chest CT scan performed after three cycles of chemotherapy. Axial contrast enhanced 
CT scan (mediastinal window) at the same level as Figure 1 shows marked improvement in 
the mass (Santos et al., 2008). 
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Scheme of bleomycin chemical sclerosis: after catheter is correctly placed and drainage is 
effective, bleomycin 10 to 20mg dissolved in 10 to 20 mL of normal saline is inserted through 
the catheter into the pericardial sac. The catheter is clamped for 1 to 2 hours and then 
reopened and allowed to drain. Special positioning of the patient is not required. Procedure 
could be repeated every 24-48h until volume of drainage was less than 25 mL per 24 hours. 
Maximum number of procedures is 3 or 4. Catheter is definitively removed when the 
echocardiogram confirms that the effusion is resolved.  
Radiation therapy has been used as adjuvant treatment in patients with incomplete tumour 
resection with or without chemotherapy (Papi et al., 2005; Suman et al., 2004) but pericardial 
mesothelioma responds poorly to radiotherapy and we have to be cautious with the side 
effects of such radiation that can cause primarily pericarditis or myocarditis.  
The use of new drugs offers further treatment options. The therapeutic schemes generally 
used are the same as those used in pleural mesothelioma, mainly a combination of platin-
infusion plus gemcitabine or paclitaxel with and objective response rates of 16-48% and 
median survivals of 9.6-11.2 months. Recently, pemetrexed, a multitargeted antifolate, has 
demonstrated modest activity against malignant pleural mesothelioma in combination with 
cisplatin (Volgenzang et al., 2003) or carboplatin (Ceresoli et al., 2006). Some cases report 
excellent tumour response with a combination of carboplatin and pemetrexed unusual in 
this type of tumours with progression-free survival and overall survival of 10 and 18 
months, respectively (Doval et al., 2007; Fujimoto et al., 2009; Santos et al., 2008), Figure 5. 
5. Conclusion 
Malignant pericardial mesothelioma is a rare malignancy with a poor prognosis. Diagnosis 
procedures are sometimes difficult and a multidisciplinary approach, including 
pathologists, clinicians and radiologist, is often required. Due to few cases being described, 
management is based on knowledge obtained from usual presentations of malignant 
mesothelioma, such as pleural or peritoneal. Systemic treatments can be used and tumoural 
responses have been described, especially with new antineoplastic agents. With respect to 
the treatment of local complications as pericardial effusions with tamponade, options 
include pericardiocentesis with or without chemical sclerosis as an initial procedure. Other 
more aggressive surgical approaches may be recommended in selected cases.  
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